Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$21.74 USD
+0.32 (1.49%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $21.74 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Silence Therapeutics PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 67 | 88 | 101 | 50 | -99,999 |
Receivables | 22 | 20 | 10 | 42 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 11 | 12 | 8 | 6 | NA |
Total Current Assets | 101 | 120 | 119 | 98 | NA |
Net Property & Equipment | 2 | 3 | 3 | 1 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 10 | 10 | 10 | 10 | NA |
Deposits & Other Assets | 3 | 0 | 0 | 0 | NA |
Total Assets | 117 | 133 | 132 | 110 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 15 | 16 | 15 | 11 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 1 | 0 | 0 | NA |
Accrued Expenses | 0 | 0 | 0 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 6 | 11 | 6 | 22 | NA |
Total Current Liabilities | 22 | 27 | 21 | 33 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 73 | 79 | 100 | 66 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 96 | 106 | 121 | 99 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 7 | 7 | 6 | 5 | NA |
Capital Surplus | 390 | 344 | 310 | 240 | NA |
Retained Earnings | -379 | -326 | -307 | -237 | NA |
Other Equity | 2 | 3 | 2 | 3 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 21 | 27 | 12 | 12 | NA |
Total Liabilities & Shareholder's Equity | 117 | 133 | 132 | 110 | NA |
Total Common Equity | 21 | 27 | 12 | 12 | 0 |
Shares Outstanding | 29.90 | 35.80 | 29.90 | 27.60 | NA |
Book Value Per Share | 0.71 | 0.76 | 0.39 | 0.42 | 0.00 |
Fiscal Year End for Silence Therapeutics PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 194 | 67 | 74 | 63 |
Receivables | NA | 24 | 22 | 22 | 32 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 13 | 11 | 14 | 8 |
Total Current Assets | NA | 230 | 101 | 111 | 103 |
Net Property & Equipment | NA | 2 | 2 | 2 | 3 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 10 | 10 | 10 | 10 |
Deposits & Other Assets | NA | 3 | 3 | 0 | 0 |
Total Assets | NA | 246 | 117 | 124 | 116 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 13 | 15 | 15 | 15 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 4 | 6 | 7 | 9 |
Total Current Liabilities | NA | 18 | 22 | 23 | 24 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 73 | 76 | 76 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 89 | 96 | 99 | 101 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 9 | 7 | 7 | 7 |
Capital Surplus | NA | 534 | 390 | 383 | 360 |
Retained Earnings | NA | -388 | -379 | -368 | -354 |
Other Equity | NA | 2 | 2 | 2 | 2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 157 | 21 | 25 | 15 |
Total Liabilities & Shareholder's Equity | NA | 246 | 117 | 124 | 116 |
Total Common Equity | 0 | 157 | 21 | 25 | 15 |
Shares Outstanding | 29.90 | 29.90 | 29.90 | 29.90 | 29.90 |
Book Value Per Share | 0.00 | 5.25 | 0.71 | 0.85 | 0.51 |